Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]

Market Overview - The indices experienced fluctuations in the afternoon, with declines narrowing. The Shanghai Composite Index reported at 4078.82 points, down 0.57%, while the Shenzhen Component Index was at 13969.10 points, down 1.32%, and the ChiNext Index at 3266.71 points, down 1.35% [1] Sector Performance - The banking sector saw significant gains, with Xiamen Bank hitting the daily limit and reaching a new high since June 2021 [1] - The innovative drug sector was notably active, with Guangsheng Tang rising over 10% [1] - The securities sector also experienced a surge, with Hualin Securities hitting the daily limit and other companies like Huaxin Securities, Huatai Securities, and Dongfang Caifu following suit [1] - The tourism and hotel sector showed strength, with Sanxia Tourism reaching the daily limit [1] - Conversely, the precious metals sector faced ongoing adjustments, with Hunan Gold and Hunan Silver hitting the daily limit down [1] - The afternoon saw weakness in the electric grid equipment stocks, with Sifang Co. hitting the daily limit down [1] Stock Movement - Overall, the market saw more stocks declining than rising, with over 3500 stocks down [1] - The beauty care, film and television, and banking sectors led in gains, while BC batteries, photovoltaic equipment, and precious metals sectors led in losses [1]

2月5日早盘，创新药概念股拉升，广生堂涨超13%，方盛制药、舒泰神、通化东宝、翰宇药业、盘龙药 业等涨幅居前。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 福建广生堂药业股份有限公司（以下简称"公司"）创新药控股子公司福建广生中霖生物科技有限公司的 在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于近日完成全部受试者入组，合计 入组578例。 GST-HG141用于慢性乙型肝炎（CHB）抗病毒药物应答不佳患者联合治疗（add-on）的随机、双盲、安 慰剂对照、多中心III期临床试验，主要目的是在经过抗病毒药物治疗的CHB应答不佳患者中评估GST- HG141治疗的有效性和安全性，联合组长单位为树兰（杭州）医院和北京大学第一医院。2026年1月， GST-HG141的III期临床及拓展研究入选新发突发与重大传染病防控国家科技重大专项"慢性乙型肝炎临 床治愈联合治疗新方案研究"项目课题三，后期拓展研究将进一步评价GST-HG141长期用药后对于 cccDNA的潜在耗竭作用，并续贯联合口服表面抗原抑制剂 GST-HG131等的临床治愈有效性，是凸显重 要临床价值的前瞻性研究。 奈瑞可韦GST-HG14 ...

北京商报讯（记者 丁宁）2月4日晚间，广生堂（300436）发布公告称，公司创新药控股子公司福建广 生中霖生物科技有限公司的在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于近日 完成全部受试者入组，合计入组578例。 公告显示，奈瑞可韦GST-HG141是新型乙肝核心蛋白/核衣壳调节剂，属于全新机制的在研抗乙肝病毒 的一类创新药。迄今为止，全球范围内尚无同类产品上市，属潜在FIC（First in class）项目。 ...

本次GST-HG141完成III期临床试验全部受试者入组后，尚需按照已制定临床方案和要求继续推进临床 试验，并经国家药品审评部门注册审批通过后方可上市。 广生堂（300436）(300436.SZ)公告，公司创新药控股子公司福建广生中霖生物科技有限公司的在研乙 肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于近日完成全部受试者入组，合计入组578 例。 ...

格隆汇2月4日丨广生堂(300436.SZ)公布，公司创新药控股子公司福建广生中霖生物科技有限公司的在 研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于近日完成全部受试者入组，合计入 组578例。 GST-HG141用于慢性乙型肝炎（CHB）抗病毒药物应答不佳患者联合治疗（add-on）的随机、双盲、安 慰剂对照、多中心III期临床试验，主要目的是在经过抗病毒药物治疗的CHB应答不佳患者中评估GST- HG141治疗的有效性和安全性，联合组长单位为树兰（杭州）医院和北京大学第一医院。2026年1月， GST-HG141的III期临床及拓展研究入选新发突发与重大传染病防控国家科技重大专项"慢性乙型肝炎临 床治愈联合治疗新方案研究"项目课题三，后期拓展研究将进一步评价GST-HG141长期用药后对于 cccDNA的潜在耗竭作用，并续贯联合口服表面抗原抑制剂GST-HG131等的临床治愈有效性，是凸显重 要临床价值的前瞻性研究。 ...

Market Overview - The chemical pharmaceutical sector increased by 0.76% on February 4, with Guangshantang leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Top Gainers in Chemical Pharmaceutical Sector - Guangshantang (300436) closed at 116.01, up 7.50% with a trading volume of 144,300 shares and a transaction value of 16.55 billion [1] - Xinlitai (002294) closed at 48.15, up 4.27% with a trading volume of 118,000 shares and a transaction value of 564 million [1] - Zehao Pharmaceutical (688266) closed at 90.30, up 4.19% with a trading volume of 31,500 shares and a transaction value of 280 million [1] - Other notable gainers include Puluo Pharmaceutical (000739) and Shutaishen (300204), with increases of 4.17% and 4.14% respectively [1] Top Losers in Chemical Pharmaceutical Sector - Xinnoway (300765) closed at 35.80, down 3.79% with a trading volume of 126,300 shares [2] - Tonghua Jinma (000766) closed at 23.57, down 3.72% with a trading volume of 352,100 shares and a transaction value of 814 million [2] - Changshan Pharmaceutical (300255) closed at 48.63, down 3.09% with a trading volume of 246,200 shares and a transaction value of 1.186 billion [2] Capital Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 39.83 million from institutional investors, while retail investors experienced a net outflow of 190 million [2][3] - Notable net inflows from institutional investors include ST Renfu (600079) with 123 million and Guangshantang (300436) with 110 million [3] - Retail investors showed significant outflows from ST Renfu (600079) and Guangshantang (300436), with outflows of 71.99 million and 86.96 million respectively [3]

本次GST-HG141完成III期临床试验全部受试者入组后，尚需按照已制定临床方案和要求继续推进临床 试验，并经国家药品审评部门注册审批通过后方可上市。 智通财经APP讯，广生堂(300436.SZ)公告，公司创新药控股子公司福建广生中霖生物科技有限公司的在 研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于近日完成全部受试者入组，合计入 组578例。 ...

奈瑞可韦 GST-HG141 是新型乙肝核心蛋白/核衣壳调节剂，属于全新机制的 在研抗乙肝病毒的一类创新药。迄今为止，全球范围内尚无同类产品上市，属潜 在 FIC（First in class）项目。Ib 期和 II 期临床试验研究结果显示，GST-HG141 片具有显著药效和良好的安全性，并且起效快，在核苷类药物治疗基础上对 HBV DNA 具有进一步显著抑制和转阴效果，且明显降低和转阴 HBV pgRNA，间接体现 了对 HBV cccDNA 的潜在有效抑制和耗竭作用，因此有潜力成为新的乙肝治疗基 石药物，重构乙肝防线。2024 年 11 月，GST-HG141 的 II 期临床研究成果被全球 肝病研究领域专业学术机构美国肝病研究协会（AASLD）作为最新突破摘要 1 证券代码：300436 证券简称：广生堂 公告编号：2026004 福建广生堂药业股份有限公司 关于乙肝治疗一类创新药奈瑞可韦 GST-HG141 完成 III 期 临床试验受试者入组的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 福建广生堂药业股份有限公司（以下简称"公司"）创新药 ...